Biopharmaceutical company Stealth Peptides has commenced patient enrolment in the Phase II study assessing Bendavia for the treatment of acute kidney injury (AKI) and renal microvascular dysfunction in hypertension.
Bendavia that targets mitochondria in order to restore bioenergetics and organ function in acute and chronic kidney diseases, is a potent compound indicated for the treatment of AKI.
Stealth CMO Dr. Richard Straube said Bendavia's therapeutic approach may prevent kidney damage by preserving mitochondrial energetics during an acute injury, improving renal function with long-term benefits.
"Bendavia has the potential to fill an unmet need for the growing number of patients with poor renal function and those experiencing kidney microvascular dysfunction," Straube added.
Phase II AKI study is designed to assess Bendavia's improvement of renal function in patients with hypertension and severe unilateral renal artery stenosis, subsequent to angioplasty treatment.
Bendavia's safety profile was established in previous clinical studies, where the compound was well tolerated and reported no serious adverse events across a dose range with highly predictable pharmacokinetics.
The beneficial renal effects and significance of the compounds novel action mechanism were established in research for acute and chronic kidney disease.
Stealth CEO Travis Wilson said, "Based on the encouraging data from our clinical and preclinical studies, we believe Bendavia is a promising therapeutic candidate for both acute and chronic kidney disease."
Bendavia, which preserves mitochondrial function under multiple pathological conditions, maintains electron transport efficiency, mitochondrial respiration and adenosine triphosphate levels, while preventing mitochondrial swelling and depolarisation.